Rapt Therapeutics, Inc. RAPT
We take great care to ensure that the data presented and summarized in this overview for RAPT Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RAPT
View all-
Medicxi Ventures Management (Jersey) LTD22.4MShares$27.3 Million7.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.16MShares$3.85 Million0.0% of portfolio
-
Column Group LLC San Francisco, CA2.68MShares$3.27 Million7.75% of portfolio
-
Black Rock Inc. New York, NY2.44MShares$2.98 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY1.73MShares$2.1 Million0.42% of portfolio
-
Ponoi Management, LLC San Francisco, CA1.6MShares$1.95 Million52.54% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.05MShares$1.28 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny960KShares$1.17 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA842KShares$1.03 Million0.01% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA800KShares$975,9730.0% of portfolio
Latest Institutional Activity in RAPT
Top Purchases
Top Sells
About RAPT
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Insider Transactions at RAPT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 23
2024
|
Column Group Ii, LP |
SELL
Other acquisition or disposition
|
Indirect |
3,198,834
-100.0%
|
-
|
|
Dec 23
2024
|
Column Group Ii, LP |
SELL
Other acquisition or disposition
|
Direct |
2,704,016
-96.43%
|
-
|
|
Jan 05
2024
|
Dirk G. Brockstedt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
898
-3.13%
|
$19,756
$22.78 P/Share
|
|
Dec 29
2023
|
Dirk G. Brockstedt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+22.81%
|
$48,000
$6.18 P/Share
|
|
Dec 21
2023
|
William Ho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-14.27%
|
$52,500
$21.68 P/Share
|
|
Nov 28
2023
|
William Ho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-7.89%
|
$19,500
$13.72 P/Share
|
|
Oct 03
2023
|
William Ho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-11.74%
|
$37,500
$15.77 P/Share
|
|
Aug 18
2023
|
William Ho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-10.51%
|
$45,000
$18.92 P/Share
|
|
Jul 28
2023
|
William Ho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
460
+1.9%
|
$5,520
$12.0 P/Share
|
|
Jun 23
2023
|
William Ho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
920
+3.79%
|
$11,040
$12.0 P/Share
|
|
Apr 19
2023
|
William Ho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-19.24%
|
$90,000
$18.88 P/Share
|
|
Apr 13
2023
|
William Ho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
460
+2.01%
|
$5,520
$12.0 P/Share
|
|
Mar 14
2023
|
Wendye Robbins |
BUY
Open market or private purchase
|
Indirect |
2,500
+27.78%
|
$50,000
$20.05 P/Share
|
|
Mar 14
2023
|
Wendye Robbins |
BUY
Open market or private purchase
|
Direct |
2,500
+5.44%
|
$47,500
$19.06 P/Share
|
|
Mar 07
2023
|
William Ho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-16.38%
|
$145,000
$29.62 P/Share
|
|
Mar 03
2023
|
William Ho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
460
+1.48%
|
$5,520
$12.0 P/Share
|
|
Jan 24
2023
|
William Ho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-14.26%
|
$150,000
$30.0 P/Share
|
|
Jan 19
2023
|
William Ho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-12.48%
|
$125,000
$25.56 P/Share
|
|
Jan 12
2023
|
William Ho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,422
+2.98%
|
$21,798
$9.15 P/Share
|
|
Jan 05
2023
|
Dirk G. Brockstedt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
742
-3.75%
|
$15,582
$21.97 P/Share
|
Last 12 Months Summary
| Other acquisition or disposition | 5.9M shares |
|---|